ERBB2 and cancer: The involvement of the YAP/TEAD axis in trastuzumab and T-DM1 resistance has been identified through multiomic analyses of HER2-positive cancer cells and tumor samples from patients resistant to anti-HER2 regimens, highlighting the enhanced expression and activation of this pathway [19–22].